The challenge in treating patients with borderline resectable pancreatic cancer is how to render tumors resectable and how to achieve the negative surgical margins that enhance long-term survival odds. Fortunately, neoadjuvant chemotherapy is helping to achieve these important goals, according to a presentation given at the 2020 Debates and Didactics in Hematology and Oncology Virtual Conference.
In a phase I trial reported in the Journal of Clinical Oncology, Andrea B. Apolo, MD, and colleagues found that the combination of cabozantinib and nivolumab, as well as the combination of cabozantinib/nivolumab plus ipilimumab, produced durable responses in patients with metastatic urothelial carcinoma and other genitourinary malignancies.
A prospective biomarker analysis of the multicohort phase II KEYNOTE-158 trial reported by Marabelle et al in The Lancet Oncology found that patients with previously treated advanced solid tumors were more likely to respond to pembrolizumab monotherapy if they had high tissue tumor mutational burden.
Combined use of aspirin, metformin, and statins may be associated with decreased lung cancer incidence and mortality, according to a study published by Kang et al in the Journal of Thoracic Oncology.